BEOVU® (Brolucizumab-dbll) entered the market in October 2019 as a new injectable drug treatment for patients with wet age-related macular degeneration (wet AMD). Wet AMD is a chronic eye disease that can lead to blurred vision and/or blind spots.
Those suffering from wet AMD saw this new treatment as a way to better manage or even improve (based on early announcements from BEOVU®’s manufacturer) their eye condition. Unfortunately, dreams of a better future instead brought new horrors to life for several wet AMD patients.
BEOVU®’s Side Effects
At the outset, the manufacturer Novartis announced the potential for certain side effects, like redness or light sensitivity, for patients who received these eye injection treatments. Unfortunately, additional concerns became evident soon after the drug’s release.
These new concerns were not included on the product label or in the information provided by Novartis to physicians and patients. These new concerns beg the question, “Is BEOVU® safe to use to treat wet AMD?”
Uncommon, Yet Significant, Adverse Reactions to BEOVU®
Adverse reactions not listed by Novartis upon its release include:
- Intraocular inflammation
- Retinal artery occlusion
- Retinal vascular occlusion
- Retinal vasculitis
- Retinal vein occlusion
- Sudden vision loss
BEOVU® Product Labels Updated, But Not Soon Enough
On June 11, 2020, the Food and Drug Administration (FDA) updated the product labels for BEOVU® to include warnings for adverse reactions like the ones listed above. The drug, however, had already been in use for approximately 8 months, meaning tens of thousands of shots had already been administered without the warnings.
Have You Suffered After Receiving BEOVU® Injections?
If you or your loved one suffered from an adverse reaction listed above after receiving injections of the BEOVU® drug, then you may be able to pursue a class action personal injury lawsuit against Novartis. And you don’t have to do it alone. Reach out to our nationally recognized law firm today.